ALZA GAINS ON CATAPRES TTS "APPROVABLE" ANNOUNCEMENT; INDEX DECLINES
Robins (up 1-1/2 to 17) and Alza (up 1-3/8 to 18-1/4) were the only point-plus gainers among listed stocks on the Pharmaceutical Component of the "F-D-C" Weekly Index for the week ended Sept. 7. Alza advanced on the announcement that Boehringer Ingelheim's Catapres TSS, a once-weekly forumulation of clonidine using Alza's controlled-release drug delivery technology, had reached the "approvable" stage at FDA. For the week, both Pharmaceutical and Diversified Components slumped 1.3%, pushing the Composite down 1.2%, while the Dow dipped 1.4%. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth